| Name | Mal-(CH2)5-Val-Cit-PAB-Eribulin |
|---|
| Description | Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules[2]. |
| References |
| Molecular Formula | C69H97N7O19 |
|---|---|
| Molecular Weight | 1328.54 |